Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction
Latest Information Update: 11 Oct 2021
Price :
$35 *
At a glance
- Drugs Lanthanum carbonate (Primary) ; Sevelamer (Primary) ; Sucroferric oxyhydroxide (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Acronyms Triple-P
- 11 Oct 2021 New trial record